<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myostatin is a negative regulator of skeletal muscle growth </plain></SENT>
<SENT sid="1" pm="."><plain>Myostatin mutations and pharmacological strategies increase muscle mass in vivo, suggesting that myostatin blockade may prove useful in diseases characterized by <z:hpo ids='HP_0003202'>muscle wasting</z:hpo>, such as the <z:hpo ids='HP_0003560'>muscular dystrophies</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We subjected the gamma-sarcoglycan-deficient (Sgcg(-/-)) mouse model of <z:hpo ids='HP_0006785'>limb-girdle muscular dystrophy</z:hpo> (LGMD) 2C to antibody-mediated myostatin blockade in vivo </plain></SENT>
<SENT sid="3" pm="."><plain>Myostatin inhibition led to increased fiber size, muscle mass, and absolute force </plain></SENT>
<SENT sid="4" pm="."><plain>However, no clear improvement in muscle histopathology was evident, demonstrating discordance between physiological and histological improvement </plain></SENT>
<SENT sid="5" pm="."><plain>These results and previous studies on the dyw/dyw mouse model of <z:hpo ids='HP_0003741'>congenital muscular dystrophy</z:hpo> and in the late-stage delta-sarcoglycan-deficient (Sgcd(-/-)) mouse model of LGMD2F document disease-specific limitations to therapeutic strategies based on myostatin blockade in the more severe mouse models of different <z:hpo ids='HP_0003560'>muscular dystrophies</z:hpo> </plain></SENT>
</text></document>